Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $18.11
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $18.11
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $18.11, but opened at $18.71. Zentalis Pharmaceuticals shares last traded at $18.71, with a volume of 1 shares.
Zentalis制药公司(纳斯达克代码:ZNTL-GET Rating)的股价周四盘前大幅上涨。该股此前收于18.11美元,开盘报18.71美元。Zentalis PharmPharmticals的股票最新报18.71美元,成交量为1股。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of research firms have recently commented on ZNTL. SVB Leerink lowered their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating for the company in a research report on Thursday, November 10th. Wedbush dropped their price objective on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating for the company in a research note on Monday, November 14th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a research report on Monday, November 14th. Oppenheimer dropped their price target on Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, November 10th. Finally, Morgan Stanley reduced their price objective on Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 11th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $46.56.
一些研究公司最近对ZNTL发表了评论。SVB Leerink在11月10日(周四)的一份研究报告中将Zentalis PharmPharmticals的目标价从42.00美元下调至27.00美元,并为该公司设定了“跑赢大盘”的评级。11月14日,周一,韦德布什在一份研究报告中将Zentalis制药公司的股票目标价从51.00美元下调至32.00美元,并为该公司设定了“跑赢大盘”的评级。在11月14日星期一的一份研究报告中,富国银行将Zentalis制药公司的股票目标价从52.00美元下调至46.00美元。奥本海默在11月10日星期四的一份研究报告中将Zentalis PharmPharmticals的目标价从80.00美元下调至50.00美元,并为该公司设定了“跑赢大盘”的评级。最后,摩根士丹利在11月11日(星期五)的一份研究报告中将Zentalis PharmPharmticals的目标价从60.00美元下调至55.00美元,并对该股设定了“增持”评级。根据MarketBeat的数据,9位研究分析师对该股的评级为买入,该公司的平均评级为“买入”,平均目标价为46.56美元。
Zentalis Pharmaceuticals Stock Performance
Zentaris制药类股表现
The stock has a fifty day moving average of $21.14 and a 200-day moving average of $24.48. The company has a market cap of $1.15 billion, a PE ratio of -4.27 and a beta of 1.80.
该股的50日移动均线为21.14美元,200日移动均线为24.48美元。该公司市值11.5亿美元,市盈率为-4.27,贝塔系数为1.80。
Insider Activity
内幕活动
Institutional Inflows and Outflows
机构资金流入和流出
Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Zentalis Pharmaceuticals by 284.2% in the 1st quarter. JPMorgan Chase & Co. now owns 105,579 shares of the company's stock worth $4,871,000 after buying an additional 78,102 shares during the period. US Bancorp DE grew its holdings in Zentalis Pharmaceuticals by 378.9% during the 1st quarter. US Bancorp DE now owns 1,451 shares of the company's stock worth $67,000 after acquiring an additional 1,148 shares in the last quarter. MetLife Investment Management LLC increased its position in Zentalis Pharmaceuticals by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 19,665 shares of the company's stock valued at $907,000 after purchasing an additional 7,139 shares during the period. Rhumbline Advisers raised its holdings in shares of Zentalis Pharmaceuticals by 7.0% in the 1st quarter. Rhumbline Advisers now owns 37,923 shares of the company's stock valued at $1,750,000 after purchasing an additional 2,475 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 79.2% in the 1st quarter. Integral Health Asset Management LLC now owns 215,000 shares of the company's stock worth $9,920,000 after purchasing an additional 95,000 shares during the period.
几家对冲基金和其他机构投资者最近买卖了该公司的股票。摩根大通在第一季度增持了Zentalis PharmPharmticals的股票,增幅为284.2%。摩根大通在此期间又购买了78,102股,目前持有105,579股该公司股票,价值4,871,000美元。美国Bancorp DE在第一季度增持了378.9%的Zentalis制药公司的股份。US Bancorp DE现在拥有1451股该公司股票,价值6.7万美元,此前在上个季度又购买了1148股。大都会人寿投资管理公司在第一季度将其在Zentalis制药公司的头寸增加了57.0%。大都会人寿投资管理公司目前持有该公司19,665股股票,价值907,000美元,在此期间又购买了7,139股。Rhumbline Advisers在第一季度将其在Zentalis PharmPharmticals的股票持有量增加了7.0%。Rhumbline Advisers现在拥有37,923股该公司股票,价值1,750,000美元,上个季度又购买了2,475股。最后,Integral Health Asset Management LLC在第一季度将其在Zentalis PharmPharmticals的股票头寸提高了79.2%。Integral Health Asset Management LLC现在拥有21.5万股该公司的股票,价值992万美元,在此期间又购买了9.5万股。
About Zentalis Pharmaceuticals
关于Zentaris制药公司
(Get Rating)
(获取评级)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis制药公司是一家临床阶段的生物制药公司,专注于发现和开发用于治疗各种癌症的小分子疗法。它的主要候选产品包括WEE1的抑制剂ZN-c3,这是一种蛋白质酪氨酸激酶,正处于治疗晚期实体肿瘤的第二阶段临床试验;作为单一疗法治疗晚期实体肿瘤的第1/2阶段临床试验,以及正在进行的与铂耐药卵巢癌患者的联合化疗的1b阶段临床试验;以及肿瘤不可知的、可预测的生物标记物的第二阶段单一治疗试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 免费获取StockNews.com关于Zentalis制药的研究报告(ZNTL)
- MarketBeat:回顾一周12/26-12/30
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
- 你应该热身到Generac股票过冬吗?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zentaris制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zentalis制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。